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ORIGINAL ARTICLE
Kidney damage, as seen in chronic renal failure
(CRF), frequently leads to anemia. Anemia can
significantly affect patient morbidity, mortality
and quality of life. The anemia of renal disease is
primarily caused by deficient production of eryth-
ropoietin.1 Recombinant human erythropoietin
(r-HuEPO) is licensed worldwide for the treatment
of anemia in CRF patients. r-HuEPO produces an
increase in red cell mass, eliminates the need for
red blood cell transfusions and mitigates the
symptoms associated with anemia.2,3 It is recom-
mended that r-HuEPO is administered two or
three times per week4 due to its relatively short
circulating half-life.
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Background/Purpose: Darbepoetin alfa can be administered less frequently than recombinant human
erythropoietin (r-HuEPO) for the treatment of anemia in chronic renal failure (CRF) patients. We aimed to
confirm that darbepoetin alfa at a reduced dosing schedule can safely maintain a target hemoglobin level
in CRF patients undergoing peritoneal dialysis.
Methods: Forty-five PD patients receiving r-HuEPO were randomized in a 1:1 ratio to continue r-HuEPO or
to change to darbepoetin alfa (open-label). Patients were maintained within a target range of hemoglobin
for 5.5 months by adjusting the dose and then the frequency of darbepoetin alfa and r-HuEPO over the
initial 4 months. The evaluation period was the final 1.5 months. A total of 37 patients completed the study.
Results: During the evaluation period, the hemoglobin of the darbepoetin alfa group was higher than that
in the baseline period (10.46 ± 0.22 g/dL vs. 9.98 ± 0.18 g/dL, p < 0.05). Hemoglobin remained similar in the
r-HuEPO group. The average dose in the darbepoetin alfa group was 93.0 μg/month, while the average
dose in the r-HuEPO group was 18,339.9 units/month. The dosing frequency was less in the darbepoetin
alfa group (3.9 times/month vs. 9.2 times/month). We divided the darbepoetin alfa group into low-dose
(< 70 μg/month) and high-dose (≥ 70 μg/month) subgroups. The body weight in the high-dose group was
higher than that in the low-dose group (66 ± 11 kg vs. 52 ± 4.4 kg, p < 0.01).
Conclusion: Both darbepoetin alfa and r-HuEPO safely maintain hemoglobin levels within the target range
in peritoneal dialysis patients. [J Formos Med Assoc 2008;107(11):843–850]
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Research has indicated that the sialic acid-
containing carbohydrate of erythropoietin deter-
mines its serum half-life.5 Darbepoetin alfa differs
from r-HuEPO by alteration of five amino acids in
the primary protein structure and two additional
carbohydrate chains allowing for an increase of
up to 22 sialic acid residues. Darbepoetin alfa can
be administered less frequently than r-HuEPO
because of an approximately three-fold longer
serum half-life and greater biological activity.6
The efficacy and safety of darbepoetin alfa have
been well studied, especially in pre-dialysis7,8 and
hemodialysis patients.9,10 Darbepoetin is also ef-
fective and safe for the treatment of anemia in peri-
toneal dialysis (PD) patients.11 The purpose of this
open-label, single-center, randomized, compara-
tive study is to confirm that darbepoetin alfa at 
a reduced dosing schedule can safely maintain a
target hemoglobin (Hb) level in end-stage renal
failure (ESRD) patients undergoing PD. Therapy
with r-HuEPO was used as reference.
Methods
Patients
Patients with ESRD undergoing PD for at least 
3 months prior to enrolment in the study were
included. Patients were 18 years or older and
clinically stable with no planned change in dialy-
sis mode. Eligibility criteria were administration 
of stable subcutaneous r-HuEPO therapy for 3
months prior to enrolment into the study and 
an Hb of 8.0–12.0 g/dL during the screening/
baseline period. There were no signs of iron defi-
ciency (serum ferritin > 100 ng/mL and transfer-
rin saturation no less than 20%). Patients were
excluded from the study if they were receiving
treatment for grand mal epilepsy or had uncon-
trolled hypertension (diastolic blood pressure 
> 100 mmHg), congestive heart failure (New York
Heart Association class III or IV), clinical evidence
of severe hyperparathyroidism (intact parathyroid
hormone [PTH] ≥ 800 pg/mL), hematologic or
systemic infection or inflammatory disease, cur-
rent active liver disease, current active peritonitis,
or current malignancy that might interfere with
the erythropoietic response. Patients with psy-
chiatric, addictive, or any disorder that compro-
mised the ability to give informed consent for
participation in this study were also excluded.
Pregnant or breast-feeding women were excluded.
Patients who had had red blood cell transfusion to
treat anemia within 1 month prior to enrolment,
or major surgery or androgen therapy within 3
months prior to enrolment in the study, were not
included.
The study was approved by the institutional re-
view board and all patients gave written informed
consent before participation.
Study design
This open-label, single-center, randomized, com-
parative study was conducted to assess the safety
and efficacy of darbepoetin alfa in ESRD patients
receiving PD. After an initial screening/baseline
period, patients currently undergoing r-HuEPO
therapy were randomized in a 1:1 ratio to either
continue r-HuEPO at their current dose, sched-
ule and route of administration or to convert to
darbepoetin alfa. Patients receiving r-HuEPO 10
times per month changed to receive darbepoetin
alfa four times per month. The monthly dose of
darbepoetin alfa for each patient was based on the
monthly r-HuEPO dose at the time of random-
ization by dividing it by 200 (Aranesp®, Product
Information Sheet). Patients receiving r-HuEPO five
times per month changed to receive darbepoetin
alfa twice per month.
Patients were maintained within a target range
of −1.0 to +1.0 g/dL of their baseline Hb level and
between Hb levels of 9.5 and 12.5 g/dL for up to
5.5 months, by adjusting the dose and frequency
of r-HuEPO and darbepoetin alfa therapy if nec-
essary. A period of 4 months was allowed after
randomization in both study arms for dose titra-
tion and stabilization of Hb level. The evaluation
period for Hb level was 1.5 months immediately
following this dose-titration period.
After completion of the study, we retrospec-
tively divided the darbepoetin alfa group into two
subgroups according to dosage. The dosages, basic
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characteristics and biochemical changes of the two
subgroups were compared.
Study endpoints
The primary endpoint of this study was to eval-
uate the mean change in Hb level between the
screening/baseline and evaluation period. Secon-
dary endpoints included the dose and frequency
of darbepoetin alfa administration during the
evaluation period, and the assessment of safety
variables.
Statistical procedures
All statistical analyses were based on two-sided
hypothesis tests with a significance level of p< 0.05.
For continuous data, the mean and 95% confi-
dence interval (CI) of change from baseline in each
treatment group were calculated. The difference be-
tween the two treatment groups was analyzed by
analysis of covariance (ANCOVA) with the baseline
value as the covariate. The difference of the mean
and 95% CI of change from baseline between the
two treatment groups was also calculated. Discrete
variables are presented as percentages and ana-
lyzed using Fisher’s exact test. The number and
percent of patients attaining a response and the
corresponding 95% CIs are also presented. For
the safety assessment, the incidence of adverse
events was compared by Fisher’s exact test.
Results
Patient characteristics
A total of 46 patients were randomized to the
trial with 22 in the darbepoetin alfa arm and 24
in the r-HuEPO arm. Among the 46 randomized
patients, a total of seven patients did not com-
plete the study (3 in the darbepoetin alfa arm, 
4 in the r-HuEPO arm). One patient in the 
r-HuEPO arm died during the screening period.
Two other patients were excluded because of in-
tact PTH > 800 pg/mL (in the darbepoetin alfa
arm) or diastolic blood pressure > 100 mmHg 
(in the r-HuEPO arm). Thirty-seven patients (18
in the darbepoetin alfa arm, 19 in the r-HuEPO
arm) were valuable for efficacy as demonstrated
in Figure 1.
Demographic and baseline characteristics were
similar between the two groups (Table 1). The 
r-HuEPO therapy was Recormon® and formulated
in a pre-filled syringe. The overall mean age of pa-
tients was 48.7 years and the mean body weight
was 58.8 kg. The most commonly reported pri-
mary causes of renal failure in the darbepoetin
alfa arm were glomerulonephritis (GN) (6 patients,
27.3%) and other causes (5 patients, 22.7%),
compared with GN (13 patients, 56.5%) and other
causes (7 patients, 30.4%) in the r-HuEPO arm.
No statistically significant difference was noted
Figure 1. Patient characteristics and
evaluability.
23 patients received
r-HuEPO
20 patients received
r-HuEPO
18 patients evaluable 19 patients evaluable
22 patients received
darbepoetin alfa
19 patients received
darbepoetin alfa
1 intolerable adverse effect
2 incomplete
1 withdrawal
2 incomplete
Screening/baseline:
Weeks −4–0
Dose titration period:
Weeks 1–16
Evaluation period:
Weeks 17–22
Completion:
Weeks 23–24
46 patients received r-HuEPO
1 patient died
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between the two groups in any baseline charac-
teristic except for intact PTH (p = 0.0376), due 
to an intact PTH level of 1295 pg/mL for one 
patient. The mean ± standard deviation of intact
PTH was 391.4 ± 309.99 pg/mL for the darbepo-
etin alfa arm, while it was 231.6 ± 156.62 pg/mL
for the r-HuEPO arm.
Efficacy of darbepoetin alfa
The mean baseline Hb level was 9.98 g/dL for
darbepoetin alfa treated patients and 9.66 g/dL for
r-HuEPO treated patients. During the evaluation
period, the mean Hb level was 10.46 g/dL (95% CI,
10.02–10.91) for the darbepoetin alfa group, and
9.78 g/dL (95% CI, 9.35–10.22) for the r-HuEPO
group (Figure 2). Both treatments maintained the
Hb concentration within our target level. Overall,
the mean change in Hb from baseline to the
evaluation period was 0.53 g/dL for the darbepo-
etin alfa group, compared with 0.08 g/dL for the
r-HuEPO group. The difference in the mean
change from baseline between the two groups
was 0.45 g/dL (95% CI, −0.06–0.95), which was
not statistically significant (p = 0.083) (Table 2).
The total dose of study drug per month is pre-
sented in Table 3. For darbepoetin alfa treated
patients, the mean monthly dose was 80.9 μg in
the titration period and 93.0 μg in the evaluation
Table 1. Patient demographics and characteristics at baseline
Darbepoetin alfa (n = 22) r-HuEPO (n = 23) Total (n = 45)
Sex
Women 10 (45.5) 15 (65.2) 25 (55.6)
Men 12 (54.5) 8 (34.8) 20 (44.4)
Age (yr) 49.5 (9.75) 48 (11.15) 48.7 (10.4)
Weight (kg) 60.5 (11.56) 57.3 (9.46) 58.8 (10.51)
Intact PTH (pg/mL) 391.4 (309.99) 231.6 (156.62) 309.7 (254.08)
Primary cause of renal failure
Diabetes 1 (4.5) 1 (4.3) 2 (4.4)
Hypertension 3 (13.6) 1 (4.3) 4 (8.9)
Glomerulonephritis 6 (27.3) 13 (56.5) 19 (42.2)
Polycystic kidney disease 2 (9.1) 1 (4.3) 3 (6.7)
Other urologic cause 1 (4.5) 0 (0) 1 (2.2)
Other 5 (22.7) 7 (30.4) 12 (26.7)
Unknown 4 (18.2) 0 (0) 4 (8.9)
Duration of PD (yr) 1.7 (1.93) 2.3 (2.49) 2.0 (2.23)
Type of dialysis
CAPD 17 (77.3) 17 (73.9) 34 (75.6)
APD 5 (22.7) 6 (26.1) 11 (24.4)
r-HuEPO = recombinant human erythropoietin; PTH = parathyroid hormone; PD = peritoneal dialysis; CAPD = continuous ambulatory
peritoneal dialysis; APD = automated peritoneal dialysis.
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Figure 2. Mean hemoglobin concentrations
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hemoglobin levels between the darbepoetin
alfa group and r-HuEPO group (p < 0.05). 
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Darbepoetin alfa for anemia in PD patients
J Formos Med Assoc | 2008 • Vol 107 • No 11 847
period. The mean monthly doses for the r-HuEPO
group were 16,089.5 units in the titration period
and 18,339.9 units in the evaluation period. The
mean monthly doses increased slightly from the
titration period to the evaluation period for both
treatment groups. In addition, the ratio of average
monthly doses (r-HuEPO/darbepoetin alfa) was
198.92 (95% CI, 150.07–278.31) during the titra-
tion period and decreased to 197.13 (95% CI,
141.68–300.41) during the evaluation period.
The most often observed dosing frequency was
less than four times a month for the darbepoetin
alfa group (17 patients, 94.4%) and nine to 12
times a month for the r-HuEPO group (9 patients,
47.4%) (Table 4). Therefore, the dosing frequency
of darbepoetin alfa (mean = 3.9) was less than that
of r-HuEPO (mean = 9.2).
Safety
A total of 436 treatment-emergent adverse events
were reported by 45 patients after randomization;
203 events were reported by 22 patients in the
darbepoetin alfa group and 233 events were re-
ported by 23 patients in the r-HuEPO group. The
most commonly reported adverse events for both
treatment groups were iron deficiency (31.32%
in darbepoetin alfa group, 45.83% in r-HuEPO
group) and edema (36.36% in darbepoetin alfa
group, 37.50% in r-HuEPO group). Except for
three adverse events reported by two patients in
Table 2. Mean change in hemoglobin values from baseline to evaluation period
Darbepoetin alfa 
r-HuEPO (n = 19) Treatment difference
Treatment 
(n = 18) effect p
Mean hemoglobin (g/dL)
Baseline (SE) 9.98 (0.18) 9.66 (0.18) 0.32 0.2243
Average during evaluation (SE) 10.46 (0.22) 9.78 (0.21) 0.68 0.033
Change from baseline (95% CI) 0.53 (0.17, 0.89) 0.08 (−0.27, 0.43) 0.45 (−0.06, 0.95) 0.083
r-HuEPO = recombinant human erythropoietin; SE = standard error; CI = confidence interval.
Table 3. Monthly total dose of study drug
Darbepoetin alfa (μg) r-HuEPO (unit) r-HuEPO/darbepoetin alfa
(n = 18) (n = 19) (95% CI)
Titration period
Mean (SD) 80.9 (43.61) 16,089.5 (4690.58) 198.92 (150.07, 278.31)
Evaluation period
Mean (SD) 93.0 (61.80) 18,339.9 (5800.75) 197.13 (141.68, 300.41)
r-HuEPO = recombinant human erythropoietin; CI = confidence interval; SD = standard deviation.
Table 4. Frequency of administration
Evaluation period Darbepoetin alfa (n = 18) r-HuEPO (n = 19) All groups (n = 37)
1–4/mo (%) 17 (94.4) 0 (0) 17 (45.9)
5–8/mo (%) 1 (5.6) 6 (31.6) 7 (18.9)
9–12/mo (%) 0 (0) 9 (47.4) 9 (24.3)
13–16/mo (%) 0 (0) 4 (21.1) 4 (10.8)
Mean (SD) 3.9 (0.96) 9.2 (3.02) 6.59 (3.48)
r-HuEPO = recombinant human erythropoietin; SD = standard deviation.
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the darbepoetin alfa arm, no other adverse events
were considered to be study-drug related. In the
darbepoetin alfa arm, two patients experienced
pruritus and one patient experienced myalgia. No
statistically significant difference in the incidence
of adverse events was found between the two
treatment groups.
A total of two serious adverse events were re-
ported by one patient in the r-HuEPO group and
the patient subsequently died. None of these two
serious adverse events were considered to be study-
drug related. One patient in the darbepoetin alfa
arm discontinued the study due to an adverse
drug reaction (general soreness).
Systolic and diastolic blood pressures were
stable throughout the study for both treatment
groups. In addition, the proportions of patients
with at least one dose of antihypertensive med-
ication decreased from the titration period to the
evaluation period. Serum ferritin levels showed a
decreasing trend and transferrin saturation levels
stabilized for both treatment groups in this trial.
Dose and patient weight
We divided the darbepoetin alfa group into low-
dose (< 70 μg/month) and high-dose (≥ 70 μg/
month) subgroups. Each subgroup included nine
patients. The high-dose group required 132.1 μg
of darbepoetin alfa per month, while the low-dose
group needed only 54 μg. The body weight of pa-
tients in the high-dose group was greater than
that in the low-dose group (66.4 ± 11.49 kg vs.
52.5 ± 4.4 kg, p < 0.01) (Table 5). The dosage of
darbepoetin alfa was not related to sex, age, peri-
toneal equilibrium test, Kt/V, baseline Hb, serum
calcium, phosphate or intact PTH levels.
Nearly 40% of patients received at least one
intravenous iron supplement during the titration
period. Serum ferritin level in the high-dose group
at week 12 was less than that at baseline (287.8 ±
93.3 ng/mL vs. 487.56 ± 133.1 ng/mL, p < 0.05)
(Table 6).
Discussion
The results of this open-label, single-center, ran-
domized, parallel trial demonstrate that darbe-
poetin alfa is as effective as r-HuEPO for treating
renal anemia in patients on PD, but with a reduced
dosing frequency. For both treatment groups, the
mean monthly dosage increased slightly from the
titration period to the evaluation period. Chang-
ing from r-HuEPO to darbepoetin alfa was not
Table 5. Darbepoetin alfa dose and patient body weight
Dose ≥ 70 μg (n = 9) Dose < 70 μg (n = 9) p
Monthly dose at titration period, μg (SD) 113.4 (39.53) 48.4 (10.23) 0.0002
Monthly dose at evaluation period, μg (SD) 132.1 (65.32) 54.0 (20.56) 0.0035
Body weight, kg (SD) 66.4 (11.49) 52.5 (4.40) 0.0058
Average dose, μg/kg/wk 0.43 0.24
SD = standard deviation.
Table 6. Summary of mean changes in serum ferritin in the darbepoetin alfa group
Dose ≥ 70 μg (n = 9) Dose < 70 μg (n = 9) Treatment difference p
Baseline, ng/mL (SE) 487.56 (133.1) 381.42 (133.1) 106.13 0.5807
Week 12, ng/mL (SE) 287.8 (93.3) 380.44 (93.3) −92.64 0.4927
Change from baseline (SE) −181.3 (35.28) −19.4 (35.28) −161.9 0.0056
Week 24, ng/mL (SE) 347.44 (118.1) 355.24 (118.1) −7.80 0.9633
Change from baseline (SE) −125.8 (69.43) −40.45 (69.43) −85.39 0.4004
SE = standard error.
associated with an increased risk of unstable Hb
levels.
Clinical studies have shown that darbepoetin
alfa safely and effectively corrects anemia in 
patients on PD using once weekly,12 once every 
2 weeks13,14 or once monthly15 dosing schedules.
These studies have also shown that darbepoetin
alfa may be administered both subcutaneously and
intravenously with similar dosing requirements.
We usually use the protein mass substitution 
formula to provide patients with a therapeutic
starting dose of darbepoetin alfa. The original
conversion rate was extended from biochemical
data where 200 units of epoetin alfa have the
peptide mass of 1 μg of darbepoetin alfa.13 The
usual dosage of darbepoetin alfa is 25 μg per week.
Analysis of data from studies performed in the
United States, Europe and Australia would sug-
gest that at higher initial epoetin alfa dosages, a
greater than 200 units to 1 μg conversion may be
applicable. In addition, at longer dosing inter-
vals, less darbepoetin alfa was required to main-
tain Hb levels relative to r-HuEPO.16,17 The dose
conversion ratio between epoetin alfa and darbe-
poetin alfa for Canada is 169:1.18 Geographic and
ethnic differences may play an important role. In
our study, the ratio of average monthly doses was
198.92:1 during the titration period and decreased
to 197.13:1 during the evaluation period. This
may be an index to predict dose conversion for
the Asian population.
The dose of darbepoetin alfa was associated
with patients’ body weight, but not baseline Hb
levels. The largest dose of darbepoetin alfa pro-
vided by the health care insurance in Taiwan is
100 μg per month, which is less than the require-
ment of our high-dose group. Iron deficiency 
can inhibit the response to darbepoetin alfa or 
r-HuEPO. The National Kidney Foundation–
Dialysis Outcomes Quality Initiative (NKF–DOQI)
guidelines advocate consistent detection and man-
agement of iron deficiency, and recommend a
ferritin level > 100 ng/mL and transferrin satura-
tion > 20%.19 Although the serum ferritin level 
in the high-dose group was maintained above
100 ng/mL during the titration and evaluation
periods, there was a statistically significant decline
in serum ferritin at week 12. Therefore, intra-
venous or oral iron should be supplied if darbe-
poetin responsiveness is poor, unless serum
ferritin is more than 500 ng/mL. When patients
are switched from r-HuEPO to darbepoetin alfa,
dose adjustments should be made as needed,
based on the individual’s Hb response, body
weight and iron status.
The safety profile of darbepoetin alfa in this
study was similar to that of r-HuEPO with respect
to type and frequency of adverse events. The ma-
jority of adverse events were related to the under-
lying disease and its treatment, and only a small
number were associated with the study drug. We
did not find any patient with pure red cell aplasia,
as recently reported,20 during our trial. Long-
term observational studies should be conducted to
establish the safety and efficacy of darbepoetin.
Several limitations in our study should be
noted. Firstly, our PD patients had a relatively
low Hb level at the screening/baseline period be-
cause of restraints in health care insurance reim-
bursement. According to the latest NKF–DOQI
guidelines,19 a target Hb level of 11–12 g/dL is
recommended. This indicated that our PD pa-
tients had an inadequate dose frequency profile of
r-HuEPO, which would probably lead to under-
or over-estimation of dose-conversion ratios.
Secondly, the observational period for safety of
darbepoetin therapy was only 1.5 months. We
might need to evaluate the efficacy and adverse
effects of darbepoetin long term.
To summarize, the efficacy profiles show that
both darbepoetin alfa and r-HuEPO safely main-
tained Hb concentrations within the target range
during the study period in CRF patients under-
going PD. Compared with the r-HuEPO group,
patients in the darbepoetin alfa group had simi-
lar Hb levels during the evaluation period and a
comparative incidence of adverse events with
less frequent dosing. Conversion from r-HuEPO
to darbepoetin alfa must be based on clinical pa-
tient data rather than on a fixed dose conversion
factor derived from a protein mass relationship.16
The dose of darbepoetin alfa was better adjusted
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by body weight. It is important to give adequate
iron when darbepoetin alfa is administered.
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